

1 **CDK12/CDK13 inhibition disrupts a transcriptional program critical for glioblastoma**
2 **survival**

3 Silje Lier, Solveig Osnes Lund, Anuja Lipsa, Katrin B. M. Frauenknecht, Idun Dale Rein, Preeti
4 Jain, Anna Ulrika Lång, Emma Helena Lång, Niklas Meyer, Aparajita Dutta, Santosh Anand,
5 Gaute Johan Nesse, Rune Forstrøm Johansen, Arne Klungland, Johanne Egge Rinholm, Stig
6 Ove Bøe, Ashish Anand, Steven Michael Pollard, Simone P. Niclou, Mads Lerdrup#, Deo
7 Prakash Pandey#

8 **#) Correspondence:**

9 Deo Prakash Pandey, Department of Microbiology, Rikshospitalet, Oslo University Hospital,
10 P. O. Box 4950 Nydalen, N-0424 Oslo, Sognsvannsveien 20, 0372 Oslo, Norway, Phone: +47
11 23 01 39 10, Fax: +47 23074061, Deo.Prakash.Pandey@rr-research.no

12 Mads Lerdrup, Center for Chromosome Stability, Department of Cellular and Molecular
13 Medicine, University of Copenhagen, Blegdamsvej 3C, 2200 Copenhagen N, Denmark, +45
14 2363 6776, mlerdrup@sund.ku.dk

15 **Affiliations:**

16 Department of Microbiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway (S.L.,
17 S.O.L., A.U.L., E.L., P.J., N.M., G.J.N., R.F.J., A.K., J.E.R., S.O.B., D.P.P.); Institute of Basic
18 Medical Sciences, University of Oslo, Oslo, Norway (S.L., N.M., J.E.R.); National Center of
19 Pathology, Laboratoire national de santé, Dudelange, Luxembourg (K.B.M.F.); Integrated
20 BioBank of Luxembourg, Luxembourg Institute of Health, Dudelange, Luxembourg (K.B.M.F.);
21 Department of Radiation Biology, Institute for Cancer Research, Radium Hospitalet, Oslo,
22 Norway (I.D.R.); Department of Computer Science and Engineering, Indian Institute of
23 Technology, Guwahati, Assam, India (A. D., A. A.); Department of Informatics, Systems, and

- 24 Communications, University of Milano-Bicocca, Milan, Italy (S.A.); MRC Centre for
25 Regenerative Medicine, SCRM Building, University of Edinburgh (S. M. P.); NORLUX Neuro-
26 Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health,
27 Luxembourg (A.L., S.P.N.); Department of Life Sciences and Medicine, University of
28 Luxembourg, Belval, Luxembourg (S.P.N.); Center for Chromosome Stability, Department of
29 Cellular and Molecular Medicine, University of Copenhagen, Denmark (M.L.).
- 30 **Running title:** CDK12/13 as therapeutic targets in glioblastoma
- 31 **Total word count** (Including abstract, text, and Figure legends): 5,365 words

32 Abstract

33 Glioblastoma is the most prevalent and aggressive malignant tumor of the central nervous
34 system. With a median overall survival of only one year, glioblastoma patients have a
35 particularly poor prognosis, highlighting a clear need for novel therapeutic strategies to target
36 this disease. Transcriptional cyclin-dependent kinases (tCDK), which phosphorylate key
37 residues of RNA polymerase II (RNAPII) c-terminal domain (CTD), play a major role in sustaining
38 aberrant transcriptional programs that are key to development and maintenance of cancer
39 cells. Here, we show that either pharmacological inhibition or genetic ablation of the tCDKs,
40 CDK12 and CDK13, markedly reduces both the proliferation and migratory capacity of glioma
41 cells and patient-derived organoids. Using a xenograft mouse model, we demonstrate that
42 CDK12/13 inhibition not only reduces glioma growth *in vivo*. Mechanistically, inhibition of
43 CDK12/CDK13 leads to a genome-wide abrogation of RNAPII CTD phosphorylation, which in
44 turn disrupts transcription and cell cycle progression in glioma cells. In summary, the results
45 provide proof-of-concept for the potential of CDK12 and CDK13 as therapeutic targets for
46 glioblastoma.

47 Significance statement

48 Glioblastoma is a common, aggressive, and invasive type of brain tumor that is usually fatal.
49 The standard treatment for glioblastoma patients is surgical resection, radiotherapy, and
50 chemotherapy with DNA-alkylating agents, and unfortunately current treatments only extend
51 overall survival by a few months. It is therefore critical to identify and target additional
52 biological processes in this disease. Here, we reveal that targeting a specific transcriptional
53 addiction for glioma cells by inhibition of CDK12/CDK13 disrupts glioma-specific transcription
54 and cell cycle progression and has potential to provide a new therapeutic strategy for
55 glioblastoma.

56 Introduction

57 With a median overall survival of 13.9 months and a 5-year survival rate of only 5.3%, IDH-
58 wildtype Glioblastoma is the most prevalent and aggressive tumor of the central nervous
59 system (1, 2). The standard of care for glioblastoma patients is surgical resection followed by
60 radiotherapy and chemotherapy with temozolomide (TMZ), which only increases overall
61 survival by a few months (3, 4). It is therefore critical to identify new specific vulnerabilities of
62 glioblastomas that can be targeted pharmacologically.

63 Aberrant transcriptional programs are key to development and maintenance of cancer cells,
64 and consequently cancer cells are often hypersensitive to the targeting of the transcriptional
65 machinery (5). Glioblastoma propagation and resistance to existing therapies are driven by a
66 subset of stem-like cells, which depend on neurodevelopmental transcription factors (TF) to
67 maintain a specific transcriptional program and sustain proliferation (6, 7). As TFs can be
68 functionally redundant or difficult to inhibit by small molecules, inhibition of the core
69 transcriptional machinery offers an attractive alternative way to disrupt the transcriptional
70 addictions of cancer cells.

71 RNAPII-dependent transcription is generally required for the transcriptional programs that
72 sustain specific cell lineages and identities, including that of glioblastomas. The transcription
73 cycle of RNAPII is regulated by a set of tCDKs, including CDK7-CDK13, that phosphorylate the
74 RNAPII CTD and facilitate key steps of transcriptional initiation and elongation(8). CDK7 is
75 involved in regulating transcriptional initiation by phosphorylating serine-5 (pSer5) of the
76 RNAPII CTD (9). CDK9, CDK12, and CDK13 phosphorylate serine-2 (pSer2) of RNAPII CTD
77 regulating transcriptional elongation (10, 11). tCDKs are attractive therapeutic targets (8), and
78 several highly specific inhibitors were recently reported (12), including the CDK9-inhibitor

79 NVP-2, the allosteric CDK7-inhibitor THZ1, and the allosteric CDK12/13-inhibitor THZ531.
80 These inhibitors target a cysteine residue outside the kinase domain, thereby resulting in
81 much higher specificity (11, 13). THZ1-mediated CDK7 inhibition leads to loss of RNAPII
82 phosphorylation mainly at Ser5 and has anti-cancer properties in adult and pediatric glioma
83 cells (14-16). THZ531 treatment reduces RNAPII phosphorylation mainly at Ser2, and can
84 reduce neuroblastoma, osteosarcoma, and Ewing sarcoma proliferation (17, 18).
85 Furthermore, the specific CDK12/CDK13 inhibitor SR-4835 reduces proliferation of triple
86 negative breast cancer cells (19).

87 Here we explore whether tCDK inhibitors can inhibit glioma cell proliferation. Using THZ531
88 and SR-4835 that inhibit CDK12/CDK13 and RNAPII pSer2^{11,19}, we demonstrate that glioma
89 cell proliferation is specifically and strongly reduced due to loss of RNAPII phosphorylation,
90 transcriptional shutdown, and disruption of a glioblastoma-specific transcriptional program.
91 Finally, we demonstrate that the cell cycle progression and DNA replication are substantially
92 affected in gliomas by CDK12/CDK13 inhibition. Altogether, our results illustrate that
93 CDK12/CDK13 inhibition can provide a promising therapeutic alternative for the treatment of
94 glioblastoma.

95 Results

96 Inhibition of CDK12/CDK13 arrests glioblastoma cell proliferation and migration

97 To identify tCDKs affecting glioblastomas proliferation, we first performed survival analysis
98 using GlioVis (20), revealing that glioblastoma patients with higher CDK13 expression have
99 significantly poorer overall survival (HR = 0.66; p = 0.0058). In contrast, no significant
100 correlation was observed for other tCDKs (Supplementary Figure 1A), although all tCDKs were
101 expressed in GSCs (Supplementary Figure 1B). We therefore examined the effect of selected

102 tCDK inhibitors on the survival of a panel of glioma-patient derived stems cells (GSCs) and
103 control cells using dose response analyses (Supplementary Figure 1, D-F). We found GSCs to
104 be particularly vulnerable to two small molecule CDK12/CDK13 inhibitors THZ531 and SR-4835
105 (11, 19) (Figure 1, A and B, Supplementary Figure 1, F and G). Furthermore, the effect was
106 independent on the presence of serum in the cell culture media (Supplementary Figure 1C).
107 Importantly, all GSCs tested were sensitive to THZ531 and SR-4835 treatment, and their IC₅₀
108 values ranging from 20 to 200 nM were substantially lower than those of cells from other
109 cancer sub-types (Figure 1B, Supplementary Figure 1F). In agreement with a recent study
110 reporting that THZ531 inhibited proliferation of liver cancer cells (21), human hepatoma
111 HepG2 cells were also sensitive to THZ531. Moreover, 100 nM and 500 nM THZ531 led to a
112 strong reduction in proliferation and colony formation for the GSCs, but not for HeLa cells
113 (Figure 1C and D, Supplementary Figure 1G). To further validate the results obtained using
114 inhibitors, we investigated the effect of genetic ablation of CDK12/CDK13 on the proliferation
115 of GSCs using a CRISPR/Cas9-based competition assay. Positive control single guide RNAs
116 (sgRNA) against MCM2, RPS19, and CDK9 inhibited glioma cells, whereas a negative control
117 had no effect. Importantly, each of three independent sgRNAs targeting CDK12, or CDK13,
118 revealed that genetic ablation of these targets significantly inhibited the glioma cell
119 proliferation (Figure 1E).

120 Cell migration is central for the invasive capacity of malignant gliomas (22), and we next
121 assessed the effect of THZ531 on GSC migration compared to the positive control Gefitinib
122 (23). High-content live-cell microscopy revealed that THZ531 significantly reduced migration
123 of G7, G144, G14 and G166 GSCs and even exceeded the ability of Gefitinib to inhibit GSC

124 migration (Figure 1F, Supplementary Figure 1H, Supplementary movies 1 and 2). These
125 findings demonstrate that THZ531 strongly inhibits proliferation and migration of glioma cells.

126 **CDK12 is expressed in human glioblastoma tissue and inhibition of CDK12/CDK13**
127 **compromises *ex vivo* glioblastoma proliferation**

128 Immunohistochemistry for CDK12 was performed on glioblastoma tissue (n = 5 patients) and
129 on CNS tissues without glioblastoma (n = 2 patients), see Supplemental Table 1 for details on
130 patient material. In control CNS tissue, no unequivocal nuclear CDK12 expression was
131 detected, while a heterogeneous distribution of nuclear CDK12 expression was visible in
132 glioblastoma tissue, ranging from weak, to moderate, to strong expression (representative
133 pictures are provided in Figure 2A, bottom panel).

134 We next assessed the effect of CDK12/CDK13 inhibitors on *ex vivo* 3D glioblastoma
135 patient-derived organoids (GBOs) that were reformed from isolated single tumor cells as
136 previously described (24, 25). Four glioblastoma patient-derived tumor cells were selected,
137 exhibiting a typical range of key glioblastoma genetic alterations including deletion of
138 CDKN2A/B, amplification of CDK4/6 and EGFR, mutations of TP53, PTEN, PIK3CA and EGFR
139 (Supplementary Figure 2B). Furthermore, in addition to the CDK12/CDK13 inhibitors, THZ531
140 and SR-4835, we included Abemaciclib, a CDK4/6 inhibitor and Lomustine, both inhibitors of
141 clinical significations for glioblastoma treatment to benchmark the effect of CDK12/CDK13
142 inhibition. THZ531 and SR-4835 treatment strongly affected the morphology and structure of
143 GBOs (Figure 2B) and inhibited the proliferation of GBOs (Figure 2, C and D). The effect of
144 THZ531 treatment on inhibition of GBO was comparable to Abemaciclib and Lomustine where
145 SR-4835 was a more potent inhibitor of GBO proliferation compared to Abemaciclib and

146 Lomustine (Figure 2, C and D), a consistent finding observed in GSCs (Supplementary Figure 2,
147 C and D).

148

149 **Inhibition of CDK12/CDK13 reduces *in vivo* tumor growth**

150 To investigate the effect of CDK12/CDK13 inhibitors can reduced tumor burden *in vivo*, we
151 used CDK12/13 inhibitor SR-4835 because it has been tested against triple-negative breast
152 tumor xenografts in mice (19), while THZ531 has not yet been used for *in vivo*. We determined
153 that in mice, the maximum tolerated dose of SR-4835 was 20 mg/kg. In addition, we
154 discovered that SR-4835 was undetectable in mouse brains when sampled 24 h post-dose,
155 suggesting that it cannot cross the blood-brain barrier (BBB). Therefore, we used a mouse
156 subcutaneous xenograft model based on U87-MG cells to test the efficacy of the CDK12/13
157 inhibitor SR-4835, and compared it to TMZ treatment. SR-4835 reduced *in vitro* U87-MG
158 proliferation with similar IC50 as we have observed for GSCs (Figure 3, A and B). Nine days
159 after injection with U87-MG cells, mice were dosed with SR-4835 or TMZ for two weeks (Figure
160 3C). Growth of subcutaneous tumors was strongly inhibited by 20 mg/kg SR-4835, 5 mg/kg or
161 2 mg/kg TMZ (Figure 3C). Importantly, the constant body weight of the mice indicated that all
162 treatments were well tolerated. Finally, we tested the effect of SR-4835 on a large panel of
163 cancer cell lines encompassing pancreatic, ovarian, uterine and prostate cancer, and found
164 that GSCs were most sensitive to CDK12/CDK13 inhibition (Figure 3D). Altogether, we found
165 that inhibition of CDK12/13 has a strong and specific effect on glioma growth, which compares
166 favorably with the existing treatment.

167 **Inhibition of CDK12/CDK13 leads to global loss of RNAPII CTD phosphorylation and nascent** 168 **mRNA synthesis in GSCs**

169 We next analyzed the phosphorylation level of key residues in the RNAPII CTD following
170 THZ531 treatment. Using 500 nM THZ531 as in previous studies of other cell types (11, 18, 26,
171 27), we found that 6 h of treatment almost completely abolished Ser2 phosphorylation and
172 strongly affected pThr4 in GSCs G7 cells, while the total RNAPII levels remained unchanged up
173 to 24 h (Figure 4A). In contrast, no substantial changes were observed in the levels of
174 phosphorylated species of RNAPII within 48 h of treatment for HeLa cells (Figure 4A).

175 To investigate the effect of CDK12/CDK13 inhibition on genome-wide chromatin occupancy of
176 total RNAPII, pSer2 and pSer5 in glioma cells, we employed the recently developed CUT&RUN
177 technology (28). Total RNAPII occupancy transiently increased at genes with preexisting
178 RNAPII at transcription start sites (TSSes) after 1 h of THZ531 treatment and were similar to
179 those of control treated cells after 6 h of treatment (Figure 4B). pSer5 levels were considerably
180 reduced post 6 h treatment, whereas genome-wide chromatin occupancy of pSer2 was
181 strongly reduced following 6 h of treatment. Control markers H3K27ac and H3K27me3 were
182 enriched at TSSes of actively transcribed and silent genes, respectively (Supplementary Figure
183 3A). In summary, these data show that THZ531 treatment strongly reduced genome-wide
184 levels of phosphorylated RNAPII species.

185 To examine nascent and steady state transcription in THZ531-treated cells, we used SLAM-seq
186 (29). In brief, uridines of nascent transcripts were labeled using a short pulse of 4-thiouridine
187 (4sU) and isolated RNA was then exposed to iodoacetate, which converts incorporated uridine
188 to cytosine. T->C conversion was used to identify nascent transcripts and compare the
189 patterns of nascent and steady state transcription in THZ531-treated and control G7 cells. This
190 established that THZ531 strongly suppressed nascent mRNA synthesis (Figure 4C). Indeed,
191 exposure to THZ531 for 6 h caused a near total loss of newly-transcribed mRNAs and also had

192 a strong impact on the composition of the steady state transcriptome, with thousands of
193 mRNAs being significantly up- and down-regulated (Figure 4, D and E).

194 As expected, the expression of mRNAs showed a very high level of concordance with total
195 RNAPII occupancy as well as RNAPII phosphorylation (Figure 4, F and G). In line with the
196 observation that THZ531 nearly completely blocked nascent transcription, the most highly
197 expressed transcripts with the highest levels of TSS-associated RNAPII, were also most strongly
198 down-regulated by THZ531 (Figure 4, F and G). Gene Ontology analysis revealed profound
199 consequences of THZ531-mediated inhibition of CDK12/CDK13, and the most strongly
200 enriched functional categories of down-regulated nascent and steady state transcripts in
201 THZ531-treated GSCs, G7 and G144, included transcription, cell cycle, and RNA metabolism
202 (Figure 4H, Supplementary Figure 3C). Up-regulated steady-state transcripts were enriched in
203 biological processes, such as translation and metabolism (Supplementary Figure 3C) in
204 accordance with previous observations (17, 18). We also investigated selected sets of
205 transcripts, including ribosomal, histones, cell cycle, house-keeping, DNA damage response
206 (DDR), BRCA-ness factors, which are known to be dependent on CDK12 for their expression
207 (18, 26), as well as the TFs that sustain the proliferation of glioma cells and their targets (Figure
208 4I). Nascent transcripts encoding cell cycle, DDR, BRCA or core glioma TFs and their target
209 genes were significantly enriched among the down-regulated genes (Figure 4, I-J,
210 Supplementary Figure 3D and 4A). In contrast, we found that nascent transcripts expressed
211 from housekeeping genes were not significantly enriched or depleted among up-regulated,
212 down-regulated, or unchanged genes.

213 Transcripts encoding key neurodevelopmental TFs, including OLIG2, POU3F2 and SOX2 are
214 required for proliferation of glioma cells, were among the most strongly down-regulated

215 transcripts (Figure 4J). The down-regulation or ablation of these TFs has been shown to
216 strongly suppress proliferation of glioma cells (6). We therefore investigated change in their
217 expression and occupancy of total, pSer2, and pSer5 forms of RNAPII following THZ531
218 treatment. All three genes were highly expressed in G7 cells and were marked by the presence
219 of super-enhancer sites containing broad H3K27ac domains, as reported earlier (6, 7)
220 (Supplementary Figure 5A). While pSer2 was nearly abolished at these genes and pSer5
221 strongly reduced, total RNAPII was also reduced following 6 h of CDK12/CDK13 inhibition. We
222 observed a strong down-regulation in the nascent transcripts for these genes, which was
223 validated using RT-qPCR. We found that the expression of key DDR genes was strongly down-
224 regulated following THZ531 treatment as reported earlier (Supplementary Figure 5B). In
225 addition, the expression of many glioblastoma-specific neurodevelopmental TFs including
226 OLIG2, POU3F2 and SOX2 target genes was profoundly down-regulated (Supplementary
227 Figure 5C), with Olig2 target genes being most strongly affected whereas expression of many,
228 but not all house-keeping genes remained unaffected (Supplementary Figure 5D). In concert,
229 these results demonstrate that THZ531-mediated inhibition of CDK12/CDK13 strongly
230 suppresses expression of TFs (and their target genes) required for the glioblastoma
231 transcriptional program.

232 **THZ531 treatment disrupts GSC cell cycle progression**

233 G7 and G144 GSCs responded similarly to THZ531 and overlapping sets of differentially
234 expressed transcripts were readily identified (Supplementary Figure 6A). Several functional
235 categories related to the cell cycle were enriched among the most down-regulated nascent
236 transcripts in THZ531-treated G7 cells and in the steady-state transcripts down-regulated in
237 both G7 and G144 cells (Figure 4H, Supplementary Figure 3C). Publicly available data on cell

238 cycle dependence of gene expression in HeLa and U2OS cells (30) were used to assess cell
239 cycle-dependence of transcriptional changes following THZ531 treatment in GSCs. The results
240 showed the strongest down-regulation of nascent transcripts in THZ531-treated G7 cells after
241 S-phase (Supplementary Figure 6, B and C). Interestingly, prior to S phase, the steady state
242 transcripts were both up- and down-regulated whereas after S-phase, the majority of the
243 steady state transcripts were down-regulated (Supplementary Figure 6, B and C).

244 To further explore the effect of CDK12/CDK13 inhibition on the cell cycle of glioma cells, we
245 used EdU incorporation to mark the cells in S-phase. Following 6 h THZ531 treatment, there
246 was no EdU incorporation in both the G7 and G144 cells, indicating a lack of DNA synthesis
247 (Figure 5, A and B) and this effect was stable up to 24 h. At the same time, we did not observe
248 any change in EdU incorporation in HeLa cells following THZ531 treatment (Supplementary
249 Figure 6D). Furthermore, we noticed an increase of cells in both G1- and G2-phases following
250 the pronounced loss of cells in active S-phase. We arrested cells in mitosis using nocodazole
251 in combination with THZ531 treatment and found that GSCs were not entering mitosis,
252 indicating blocked cell cycle progression (Figure 5, C and D). Furthermore, neither the
253 frequency of apoptosis nor the amount of DNA damage changed after 6 h exposure to THZ531.
254 However, after exposure to THZ531 for 24 h, apoptotic cells, DNA damage, γ -H2AX and cleaved
255 PARP did increase (Figure 5, E-G). Expression of key cyclin genes, which are required for
256 different phases of cell cycle was found to be severely down-regulated following THZ531
257 treatment (Figure 5H), explaining the arrested cell cycle progression. These data indicate that
258 THZ531 impacts DNA synthesis and cell cycle progression of glioma cells, in addition to
259 blocking nascent transcription and phosphorylation of RNAPII CTD.

260 Discussion

261 In the present study, we identify an efficient and specific way to target and disrupt the
262 transcriptional program required for glioma cell proliferation and migration. Specifically, we
263 show how small molecule inhibitors targeting CDK12/CDK13, which phosphorylate RNAPII,
264 strongly perturb the transcriptional landscape in GSCs. This leads to down-regulation of
265 multiple glioblastoma-associated transcription factors and their targets, and subsequently a
266 strong inhibition of GSC-proliferation, stalled cell cycle progression, and induction of cell
267 death. The clear dependence of glioma cells on CDK12 and CDK13 for proliferation was
268 validated using CRISPR/CAS9-mediated genetic ablation of CDK12 and CDK13. We also
269 confirmed that CDK12 is well-expressed in human glioblastoma tissue ranging from weak to
270 moderate to strong expression. Moreover, the CDK12/CDK13 inhibitors affected the
271 morphology and reduced the survival of ex vivo GBOs, in a favorable manner compared to
272 CDK4/6 inhibition and Lomustine, both of which are used to treat glioblastoma patients. While
273 our results show that the CDK12/CDK13 inhibitor SR-4835 is well-tolerated in mice, it fails to
274 cross the BBB. However, the observed reduced tumor burden in a subcutaneous xenograft
275 mouse model, encourages further tests in more clinically relevant *in vivo* models as well as
276 identification of novel CDK12/13 inhibitors that can pass the BBB.

277 The primary activity of CDK12 and CDK13 is to phosphorylate Ser2 of RNAPII CTD (8) and
278 exposure to THZ531 rapidly and nearly completely blocks phosphorylation of RNAPII Ser2 and
279 strongly reduces abundance of other RNAPII phospho-species in GSCs, with no similar effect
280 in control cells. Furthermore, pSer2- and pSer5- RNAPII chromatin occupancy is strongly
281 reduced in THZ531-treated glioma cells, while total RNAPII chromatin occupancy is not. In
282 addition, exposure of glioma cells to THZ531 nearly abolishes nascent mRNA synthesis and

283 causes large-scale changes in steady state mRNA expression. In particular, THZ531 strongly
284 down-regulates expression of TFs and transcriptional programs essential for glioma cell
285 proliferation (6).

286 We find that CDK12/CDK13 inhibition has a profound impact on expression of genes involved
287 in transcription and cell cycle regulation. Concordantly, THZ531 rapidly suppresses active DNA
288 replication and increases the proportion of cells in G1 and G2 in GSCs. However, apoptosis and
289 DNA damage are observed after 24 h exposure to THZ531, but not after 6 h. These
290 observations suggest that THZ531 compromises DNA synthesis, and that this subsequently
291 may lead to DNA damage and apoptosis. At the same time, we find that the expression of key
292 cyclin genes together with core DDR genes is profoundly down-regulated within 6 h treatment
293 of THZ531, explaining the remarkable arrest of cell cycle progression. Glioblastomas have
294 constitutive activation of the DDR pathway and show high genomic instability (31-33), and
295 several key regulators of the DDR pathways, including BRCA1, are required for glioblastoma
296 survival ⁴¹. We find that key DDR components are suppressed rapidly and strongly by
297 CDK12/CDK13 inhibition, providing a potential explanation for the remarkable sensitivity of
298 GSCs compared to other cancer cells (Figure 3F).

299 Since the initial identification of THZ531 in 2016, there has been great interest in
300 understanding the requirement and roles of CDK12/CDK13 in cancer cells. Furthermore, loss
301 or mutation of CDK12 is reported for several cancers, including ovarian, breast and prostate
302 cancers (34-36). These studies correlate loss of CDK12 with altered expression of core DNA
303 damage response genes. Recent studies associated expression changes after loss of
304 CDK12/CDK13 with gene length, expression level, and intronic polyadenylation cleavage of
305 affected mRNAs (17, 18, 26). In agreement with other studies focusing on breast cancer and

306 neuroblastomas (17-19, 26), we find that the inhibition of CDK12/CDK13 strongly down-
307 regulated the expression of core DDR genes. Furthermore, our observations are in agreement
308 with recent findings in K562 chronic myeloid leukemia cells, where inhibition of CDK12/13
309 result in a global loss of RNAPII CTD phosphorylation and extensive genome-wide
310 transcriptional changes (27). Moreover, similar results are obtained when CDK12 is inhibited
311 in HEK-293 cells (37). At higher concentrations, we observe that the proliferation of control
312 cells is also affected by both CDK12/CDK13 inhibitors, THZ531 and SR-4835. Therefore, other
313 cancer cells potentially require a higher dose of CDK12/CDK13 inhibitors to observe the global
314 changes in RNAPII phosphorylation and subsequent shutdown of nascent transcription. It will
315 be relevant for future work to understand the factors that govern the differences leading to
316 sensitivity of CDK12/13 inhibition among different cancers.

317 Taken together, we report that inhibition of CDK12/CDK13 leads to a global down-regulation
318 of transcription and limits cell cycle progression in glioma cells. We also demonstrate that
319 pharmacological inhibition of CDK12/CDK13 profoundly reduces the *in vitro* and *ex vivo*
320 proliferation of glioma cells and reduces tumor burden in a subcutaneous mouse xenograft
321 model. CDK12/13 inhibition leads to a therapeutically attractive outcome by exploiting a
322 transcriptional addition without directly targeting DNA replication machinery. Identification
323 and further characterization of small molecule inhibitors targeting CDK12/CDK13 with
324 improved pharmacological properties, in particular the ability to cross the BBB, therefore
325 would have a large therapeutic potential for glioblastoma treatment. The potential of
326 CDK12/13 inhibitors for glioblastoma treatment should be investigated further.

327 **Materials and methods**

328 **Cell culture**

329 All the GSCs used are IDH-wt. GSCs G7, G144, G166, G14, G25, G26 and G30 were a kind gift
330 from S.M. Pollard. GSC cell lines U3013 and U3017 were acquired from HGCC, Uppsala (38).
331 GSC cell lines P3, BG5 and BG7 were a kind gift from Rolf Bjerkvig (39). All GSC cells were
332 cultured in neural stem cell (NSC) medium supplemented with EGF and FGFb as previously
333 described(40). U87MG, Hela, U2OS and HEPG2 cell lines were cultured in DMEM with FBS.
334 MCF10a and breast cancer cell lines, MCF-7, SKBR-3 and MDA-MB-231 were kind gifts from
335 Prof. Ragnhild Eskeland, University of Oslo and Dr. Gunnhild Mælandsmo, Oslo University
336 Hospital, Oslo.

337 **Cell viability assays**

338 **MTT assay;** 3K-10K cells were seeded in 96-well plates and treated with inhibitors. After 72
339 hours (h), the MTT assay (Merck, 11465007001) was performed, according to manufacturer's
340 instructions. **Proliferation assay;** 200,000 cells were seeded in duplicate in 6-well plates. Cells
341 were counted with trypan blue and replated every 3-4 days. **Clonogenic survival assay;** 10,000
342 cells were seeded in duplicate in 6-well plates. After 14 days, the medium was removed and
343 cells were given a wash with PBS. Crystal violet staining (0.05% Crystal violet, 1% CH₂O, 1%
344 MeOH in PBS) was added for 20 minutes (min), after which the cells were rinsed with water
345 and left to air dry. **Ex vivo assay** was performed on standardized 3D patient-derived organoids
346 from glioblastoma IDH-wt patients that were reformed from isolated single tumor cells as
347 previously described (24, 25). More information in supplemental methods. **Competition**
348 **assays** were performed as described in supplemental methods.

349 **Cell migration experiment**

350 Migration patterns of GSCs were studied in 96-well glass bottom plates (Greiner Sensoplate
351 (M4187-16EA, Merck)) after treatment with DMSO control, 500 nM THZ531 or 1.0 μ M
352 Gefitinib overnight. More information is provided in the supplemental methods section.

353 **Immunohistochemistry for CDK12 expression in human glioblastoma tissue**

354 Immunohistochemistry (IHC) for CDK12 expression was performed with polyclonal rabbit-anti-
355 human-CDK12 antibody (ab246887; Abcam; dilution 1:50) using the protocol described in
356 supplementary methods section. To determine the expression of CDK12 in human patients,
357 we assessed glioblastoma and control tissue for immunoreactivity to CDK12 (Figure 2A and
358 Supplementary Figure 2A). A brief description of patient characteristics is included in
359 supplemental Table 1.

360 **Mouse experiments**

361 SR-4835 (MedChemexpress) was dissolved in 10% DMSO / 90% (30%) Hydroxypropyl-b-
362 Cyclodextrin (hp-BCD) and TMZ (Selleckchem), was dissolved in 10% DMSO in distilled water
363 and administered per os (PO) using gavage. Weekly SR-4835 dosage was five days daily in the
364 week with a two-day break whereas TMZ dosage was daily. For the combination treatment,
365 compounds were dosed at the same time with TMZ dosed first, followed by SR-4835. More
366 information is provided in the supplemental methods section.

367 **Ethics**

368 For glioma organoids, patient samples were collected from patients having given informed
369 consent, and ethical approval has been obtained from the research ethics committee in
370 Luxembourg (National Committee for Ethics in Research (CNER), as described (24). The use of
371 fully anonymised human tissue (IHC) was also approved by CNER (reference number 1121-

372 278). Mice experiments were carried out by Crownbio, UK and animal welfare were complied
373 with the UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU
374 of the European Parliament and the Council of 22 September 2010 on the protection of
375 animals used for scientific purposes.

376 **SR-4835 dose response** 3K-5K cells were seeded in 96-well plates and next day, were treated
377 with 3.16-fold dilution in triplicate (31.6 μ M, 10 μ M, 3.16 μ M, 1 μ M, 316nM, 100nM, 31.6nM,
378 10nM and 3.16nM). After 72h, CellTiter-Glo assay (Promega) was performed, according to
379 manufacturer's instructions. The IC50 data used for Figure 3F is available on request.

380 **Immuno-blotting**

381 Cells were lysed directly in 1.25X Laemmli sample buffer, sonicated and denatured at 95°C for
382 5 minutes. Samples were loaded and the protein separated in Novex tris-glycine 6% gels (Life
383 Technologies, XP00062BOX) and transferred to nitrocellulose membranes, subsequently
384 standard immuno-blotting procedures were followed with details provided in the
385 supplemental methods section.

386 **SLAM-seq and CUT&RUN**

387 Cells were treated with THZ531 or vehicle control before they were harvested and were
388 processed using the protocol described in (29)(28), with details described in the supplemental
389 methods section.

390 **Bioinformatics and data processing**

391 Please see the supplemental methods section for details on SLAM-seq data processing,
392 CUT&RUN and visualization methods.

393 **Flow cytometry**

394 Cell cycle changes were analysed using the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay
395 Kit (Invitrogen, CA, USA). Cells were labeled with EdU for 3 h after drug treatment with
396 THZ531. Dead cells were marked using LIVE/DEAD Near-IR (Life Technologies, L10119), and
397 Hoechst was used to mark DNA. Flow cytometry was performed using BD Fortessa (BD
398 Biosciences, CA, USA). Analyses were made using the Flowjo software (FlowJo, LLC, OR, USA).

399 **Data Availability**

400 ----- FOR REVIEWERS (will be deleted from the manuscript upon acceptance): -----
401 To review GEO accession GSE174035:
402 Reviewer access to the unpublished Cut&Run and SLAM-seq data in this study can be
403 obtained using the link <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE186311>
404 and by entering the token **inyvokisndmtpqz** into the box.
405 -----

406 All Cut&Run and SLAM-seq data are deposited at NCBI's Gene Expression Omnibus (41) under
407 the accession number GSE186311.

408 **Acknowledgements**

409
410 We would like to thank the AML and Flow Cytometry Core Facility at Oslo University Hospital
411 for help with microscopy and flow cytometry experiments.

412 **Declaration:** The authors declare no potential conflicts of interest.

413 **Funding:** D.P.P. was supported by funding from the health southeast region agency, Norway
414 (HSØ 2018045 and HSØ 2021037), Nansen fond and SPARK programme from University of
415 Oslo. Si.L. was supported by scholarship from the Medical Student Research Program,
416 University of Oslo, Norway. M.L. was supported by the Danish National Research Foundation
417 (DNRF115). A.L. and S.P.N. were supported by the National Research Fund (FNR) of
418 Luxembourg (C20/BM/14646004/GLASS-LUX).

419 References

- 420 1. R. G. Verhaak *et al.*, Integrated genomic analysis identifies clinically relevant subtypes
421 of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
422 *Cancer Cell* **17**, 98-110 (2010).
- 423 2. C. W. Brennan *et al.*, The somatic genomic landscape of glioblastoma. *Cell* **155**, 462-
424 477 (2013).
- 425 3. M. E. Hegi *et al.*, MGMT gene silencing and benefit from temozolomide in
426 glioblastoma. *N Engl J Med* **352**, 997-1003 (2005).
- 427 4. J. R. Perry *et al.*, Short-Course Radiation plus Temozolomide in Elderly Patients with
428 Glioblastoma. *N Engl J Med* **376**, 1027-1037 (2017).
- 429 5. J. E. Bradner, D. Hnisz, R. A. Young, Transcriptional Addiction in Cancer. *Cell* **168**, 629-
430 643 (2017).
- 431 6. M. L. Suva *et al.*, Reconstructing and reprogramming the tumor-propagating potential
432 of glioblastoma stem-like cells. *Cell* **157**, 580-594 (2014).
- 433 7. S. C. Mack *et al.*, Chromatin landscapes reveal developmentally encoded
434 transcriptional states that define human glioblastoma. *J Exp Med* **216**, 1071-1090
435 (2019).
- 436 8. J. Chou, D. A. Quigley, T. M. Robinson, F. Y. Feng, A. Ashworth, Transcription-Associated
437 Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. *Cancer*
438 *Discov* **10**, 351-370 (2020).
- 439 9. C. L. Christensen *et al.*, Targeting transcriptional addictions in small cell lung cancer
440 with a covalent CDK7 inhibitor. *Cancer Cell* **26**, 909-922 (2014).
- 441 10. C. M. Olson *et al.*, Pharmacological perturbation of CDK9 using selective CDK9
442 inhibition or degradation. *Nat Chem Biol* **14**, 163-170 (2018).
- 443 11. T. Zhang *et al.*, Covalent targeting of remote cysteine residues to develop CDK12 and
444 CDK13 inhibitors. *Nat Chem Biol* **12**, 876-884 (2016).
- 445 12. S. J. Vervoort *et al.*, Targeting transcription cycles in cancer. *Nat Rev Cancer* **22**, 5-24
446 (2022).
- 447 13. N. Kwiatkowski *et al.*, Targeting transcription regulation in cancer with a covalent CDK7
448 inhibitor. *Nature* **511**, 616-620 (2014).
- 449 14. S. A. Greenall *et al.*, Cyclin-dependent kinase 7 is a therapeutic target in high-grade
450 glioma. *Oncogenesis* **6**, e336 (2017).
- 451 15. S. Nagaraja *et al.*, Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
452 *Cancer Cell* **31**, 635-652 e636 (2017).
- 453 16. W. Meng *et al.*, CDK7 inhibition is a novel therapeutic strategy against GBM both in
454 vitro and in vivo. *Cancer Manag Res* **10**, 5747-5758 (2018).
- 455 17. I. Bayles *et al.*, Ex vivo screen identifies CDK12 as a metastatic vulnerability in
456 osteosarcoma. *J Clin Invest* **129**, 4377-4392 (2019).
- 457 18. M. Krajewska *et al.*, CDK12 loss in cancer cells affects DNA damage response genes
458 through premature cleavage and polyadenylation. *Nat Commun* **10**, 1757 (2019).
- 459 19. V. Quereda *et al.*, Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast
460 Cancer. *Cancer Cell* **36**, 545-558 e547 (2019).
- 461 20. R. L. Bowman, Q. Wang, A. Carro, R. G. Verhaak, M. Squatrito, GlioVis data portal for
462 visualization and analysis of brain tumor expression datasets. *Neuro Oncol* **19**, 139-141
463 (2017).

- 464 21. C. Wang *et al.*, CDK12 inhibition mediates DNA damage and is synergistic with
465 sorafenib treatment in hepatocellular carcinoma. *Gut* **69**, 727-736 (2020).
- 466 22. V. A. Cuddapah, S. Robel, S. Watkins, H. Sontheimer, A neurocentric perspective on
467 glioma invasion. *Nat Rev Neurosci* **15**, 455-465 (2014).
- 468 23. E. Lang *et al.*, Coordinated collective migration and asymmetric cell division in
469 confluent human keratinocytes without wounding. *Nat Commun* **9**, 3665 (2018).
- 470 24. A. Golebiewska *et al.*, Patient-derived organoids and orthotopic xenografts of primary
471 and recurrent gliomas represent relevant patient avatars for precision oncology. *Acta*
472 *Neuropathol* **140**, 919-949 (2020).
- 473 25. A. Oudin *et al.*, Protocol for derivation of organoids and patient-derived orthotopic
474 xenografts from glioma patient tumors. *STAR Protoc* **2**, 100534 (2021).
- 475 26. S. J. Dobbury, P. L. Boutz, P. A. Sharp, CDK12 regulates DNA repair genes by suppressing
476 intronic polyadenylation. *Nature* **564**, 141-145 (2018).
- 477 27. Z. Fan *et al.*, CDK13 cooperates with CDK12 to control global RNA polymerase II
478 processivity. *Sci Adv* **6** (2020).
- 479 28. M. P. Meers, T. D. Bryson, J. G. Henikoff, S. Henikoff, Improved CUT&RUN chromatin
480 profiling tools. *Elife* **8** (2019).
- 481 29. M. Muhar *et al.*, SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC
482 axis. *Science* **360**, 800-805 (2018).
- 483 30. J. Bostrom *et al.*, Comparative cell cycle transcriptomics reveals synchronization of
484 developmental transcription factor networks in cancer cells. *PLoS One* **12**, e0188772
485 (2017).
- 486 31. S. Bao *et al.*, Glioma stem cells promote radioresistance by preferential activation of
487 the DNA damage response. *Nature* **444**, 756-760 (2006).
- 488 32. J. Bartkova *et al.*, Replication stress and oxidative damage contribute to aberrant
489 constitutive activation of DNA damage signalling in human gliomas. *Oncogene* **29**,
490 5095-5102 (2010).
- 491 33. R. D. Rasmussen *et al.*, BRCA1-regulated RRM2 expression protects glioblastoma cells
492 from endogenous replication stress and promotes tumorigenicity. *Nat Commun* **7**,
493 13398 (2016).
- 494 34. K. M. Ekumi *et al.*, Ovarian carcinoma CDK12 mutations misregulate expression of DNA
495 repair genes via deficient formation and function of the Cdk12/CycK complex. *Nucleic*
496 *Acids Res* **43**, 2575-2589 (2015).
- 497 35. S. F. Johnson *et al.*, CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor
498 Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
499 *Cell Rep* **17**, 2367-2381 (2016).
- 500 36. Y. M. Wu *et al.*, Inactivation of CDK12 Delineates a Distinct Immunogenic Class of
501 Advanced Prostate Cancer. *Cell* **173**, 1770-1782 e1714 (2018).
- 502 37. M. Tellier *et al.*, CDK12 globally stimulates RNA polymerase II transcription elongation
503 and carboxyl-terminal domain phosphorylation. *Nucleic Acids Res* **48**, 7712-7727
504 (2020).
- 505 38. Y. Xie *et al.*, The Human Glioblastoma Cell Culture Resource: Validated Cell Models
506 Representing All Molecular Subtypes. *EBioMedicine* **2**, 1351-1363 (2015).
- 507 39. J. Wang *et al.*, A reproducible brain tumour model established from human
508 glioblastoma biopsies. *BMC Cancer* **9**, 465 (2009).

- 509 40. S. M. Pollard *et al.*, Glioma stem cell lines expanded in adherent culture have tumor-
510 specific phenotypes and are suitable for chemical and genetic screens. *Cell Stem Cell*
511 **4**, 568-580 (2009).
512 41. R. Edgar, M. Domrachev, A. E. Lash, Gene Expression Omnibus: NCBI gene expression
513 and hybridization array data repository. *Nucleic Acids Res* **30**, 207-210 (2002).
514

515 Figure legends

516 **Figure 1**

517 **Inhibition of CDK12 and CDK13 specifically affects proliferation of glioma cells. (A)** Dose-
518 response curves from MTT assays eleven high-grade glioma and seven non-glioma cell lines
519 treated with THZ531. Data represent mean \pm SD of three replicates. **(B)** Bar graph showing
520 IC50 values from the MTT assays in (A). **(C)** *in vitro* cell proliferation assay of the GSCs G7 and
521 G144, and HeLa cells treated as indicated. Data represent mean \pm SD of three replicates. **(D)**
522 Clonogenic survival assay of G7, G144 and HeLa cells treated as indicated. **(E)** Competition
523 assays of sgRNAs targeting CDK9, CDK12 and CDK13 as well as positive controls (essential
524 genes, MCM2 and RPS19). Non-targeting sgRNA (NC) was used as negative control. **(F)** Boxplot
525 representing average migration speed of four high-grade glioma cells treated as indicated. The
526 EGFR inhibitor Gefitinib was used as positive control. Each data-point boxplots represents
527 average migration speeds in 4-6 acquired time-lapse movies. The boxplot is representative of
528 three independent experiments. * $p < 0.01$, ** $p < 0.001$.

529

530 **Figure 2**

531 **CDK12 is expressed in resected glioblastoma tissue of human patients and inhibition of**
532 **CDK12/CDK13 compromises ex vivo glioblastoma proliferation. (A)** Representative images of
533 CDK12 immunohistochemistry in control and glioblastoma tissue. The top row shows control
534 stainings whereas the bottom row left to right reflect CDK12 expression in three different

535 glioblastoma patients (for information on patients, see Supplementary Table 1). Scale bar 50
536 μM . **(B)** Representative image showing effect of different inhibitors with indicated doses on
537 glioblastoma organoids. **(C)** Dose-response curve showing data from glioblastoma organoids
538 treated with inhibitors as indicated and measured for cell viability 72 h post treatment. **(D)**
539 Dot-plot showing IC50 values from the assays in **(C)**.

540 **Figure 3**

541 **Inhibition of CDK12/CDK13 reduces tumor burden *in vivo*.** **(A)** Dose-response curve for U87-
542 MG glioma cells treated with SR-4835. Data represent mean \pm SD of three replicates. **(B)** *in*
543 *vitro* cell proliferation assay U87-MG cells treated as indicated. Data represent mean \pm SD of
544 three replicates. **(C)** Mean tumor volume and relative body weight of mice over time for the
545 indicated treatments with the dosage shown in the bottom. Significance of the combination
546 treatment is indicated with an asterisk. **(D)** Box-plot showing IC50 values for dose response of
547 SR-4835 inhibition on a panel of cancer cell lines. p-values are from two-sided t-tests
548 Benjamini-Hochberg corrected for multiple testing.

549 **Figure 4**

550 **CDK12/CDK13 inhibition profoundly affects RNAPII phosphorylation and transcription in**
551 **glioma cells.** **(A)** Immuno-blot analyses from G7 and HeLa cells that were treated with vehicle,
552 500 nM THZ531 for 6 h, 24 h and 48 h for the various RNAPII CTD species. **(B)** Heatmaps of
553 Cut&Run signal from RNAPII, RNAPII phosphorylation states, and histone modifications at k-
554 means clustered unique TSSes \pm 1 kbp. G7 cells were treated with DMSO and THZ531 for 1 h
555 and 6 h. **(C)** Diagram showing T to C conversion in three replicates of SLAM-seq data from G7
556 cells treated with THZ531 or DMSO for 6 h. **(D)**-**(E)** 'Volcano plots' showing the overall
557 transcriptional differences in G7 cells treated with THZ531 for 6h compared to DMSO control
558 for steady-state **(D)** and nascent transcripts **(E)**. X-axis shows the log2 fold differences. Y-axis

559 shows the $-\log_{10}$ Benjamini-Hochberg corrected p-values. Dashed rectangles: populations of
560 interest. **(F)** Graphs of average Cut&Run signal from RNAPII, RNAPII phosphorylation states,
561 and histone modifications at and around TSS and TTS of genes. Levels are FPKM normalized.
562 **(G)** Heatmaps illustrating transcription in relationship to Cut&Run data of RNAPII, RNAPII
563 phosphorylation states, and histone modifications at TSSes. Groups from Figure 4E **(H)** Bar
564 diagrams of Benjamini-Hochberg corrected $-\log_{10}$ p-values from most enriched gene ontology
565 terms in nascent or steady state transcripts down-regulated after 6h of THZ531-treatment in
566 G7 cells. **(I)** Bubble diagram of enrichment of gene groups within up-regulated, down-
567 regulated or unchanged categories. P-values are Benjamini-Hochberg corrected). **(J)** Volcano
568 plots as in Figure 4E with the indicated gene populations colored.

569 **Figure 5**

570 **CDK12/CDK13 inhibition disrupts glioma cell cycle** **(A)** Cell cycle analysis in G7 and G144 cells
571 after 6 and 24 h treatment with DMSO or 500 nM THZ531. 10 μ M EdU was added 1 h prior to
572 harvest. Dot plots show intensity of EdU relative to DNA content (Hoechst) in interphase cells
573 (one representative replicate shown). **(B, C)** Bar diagrams of cell cycle distributions of G7 and
574 G144 cells treated as indicated. Doses used: THZ531 (500 nM) Nocodazole (1 μ g/ml). **(D)** Flow
575 cytometry analysis of % of G7 cells in mitosis following 500 nM THZ531 \pm 1 μ g/ml Nocodazole
576 treatment for 24h. Data represent mean \pm SD of two replicates for **(B)-(D)**. **(E, F)** Flow
577 cytometric assays of apoptotic **(E)** of γ H2AX accumulation **(F)** cells in G7 cells treated with 500
578 nM THZ531 for 6 h and 24 h. **(G)** Western blots of PARP and γ H2AX levels in G7, G144 and
579 HeLa cells treated with 500 nM THZ531. **(H)** RT-qPCR analysis of cyclin mRNA levels in G7 cells
580 treated with 500 nM THZ531 for 1 h and 6 h. Data represent mean \pm SD of two replicates.

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



Supplemental methods

Lentivirus production and transduction

For lentivirus production, 293FT cells were transfected with VSV, Pax8 and expression constructs, using lipofectamine. After 8h, cells were washed and cultured in NSC medium. After 48h, the medium was collected and passed through a 0.45 μm filter. For transduction, GSCs were cultured in NSC medium containing virus particles supplemented with 8 $\mu\text{g}/\text{ml}$ polybrene. After 48h of transduction, cells were passaged and cultured in selection medium for 2 days.

Competition assay

Stably expressing Cas9 G7 cells are derived by transducing GSC G7 cells with lentivirus produced from lentiCas9-Blast (Addgene #52962). The sgRNAs were expressed from U6-sgRNA-SFFV-puro-P2A-EGFP, which is derived from (Addgene: #57827) and reported here ²⁵. The sgRNA sequences are available on request. The stably expressing Cas9 G7 cells were transduced with the sgRNAs expressing lentiviruses to achieve 40-60% GFP expressing cells. The transduced cells were subsequently cultured for a period of 21 days and population of sgRNA expressing GFP+ cells were analyzed at indicated days by flow cytometry.

Cell migration experiment

Migration patterns of human GSCs were studied in 96-well glass bottom plates (Greiner Sensoplate (M4187-16EA, Merck)) after treatment with DMSO control, 500 nM THZ531 or 1.0 μM Gefitinib overnight. Live cell imaging was performed using an ImageXpress Micro Confocal High-Content microscope equipped with an environmental control gasket, maintaining 37°C and 5% CO₂, and controlled by the MetaXpress 6 software (Molecular Devices). Images were acquired in widefield mode using a 20x 0.45 NA Ph1 air objective, a phase contrast ring, and

transmitted light for visualizing the contour of cells. Cell migration was registered for a total time of 8 h (h). For each well 2 sites were imaged with a time interval of 4 minutes (min) between frames. Acquired time lapse movies were analyzed using the TrackMate²⁵ plugin in the Fiji ImageJ software²⁶ and *in-house* Python-based scripts (Python 3.7.6).

Ex vivo assay were performed on standardized 3D patient-derived organoids that were reformed from isolated single tumor cells as previously described {Golebiewska, 2020 #163; Oudin, 2021 #164}. For the CDK12/CDK13 inhibitors, four patient-derived GBM IDHwt tumor cells, exhibiting a typical range of key GBM genetic alterations including deletion of CDKN2A/B, amplification of CDK4/6 and EGFR, mutations IN TP53, PTEN, PIK3CA, EGFR were selected. Briefly, isolated tumor cells were seeded in a 384-well plate at a density of 1000 cells/well and were cultured on an orbital shaker for 72 hours to reform organoids prior to inhibitor treatment. 3D organoids were cultured in a volume of 25 μ l DMEM medium/well supplemented with 10% FBS, 2mM L-Glutamine, 0.4mM NEAA, and 100U/ml Pen/Strep (all from Lonza) at 37°C under 5% CO₂ and atmospheric oxygen. Organoids were treated with the following inhibitors: THZ531 (CDK12/13), SR4835 (CDK12/13), Abemaciclib (CDK4/6) and Lomustine from MedChemExpress in a twofold and six-point serial dilution series ranging from 16 μ M to 500 nM (THZ531), 4 μ M to 125nM (SR4835) and 32 μ M to 500 nM (Abemaciclib and Lomustine) from a stock solution of 10 mM prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich). A set of control wells with cells treated with DMSO was included on all the plates and the assay was performed with three technical replicates. After 3 days (72 hours) of incubation with the inhibitors, cell viability was measured using the commercially available CellTiter-Glo® 3D Cell Viability Assay (Promega) according to the manufacturer's instructions. Luminescence was measured with a ClarioStar plate reader (BMG Labtech). The relative cell viability for each

inhibitor was calculated by normalization to DMSO control per condition. Dose response curves (DRCs) were fitted by nonlinear regression analysis using GraphPad Prism software: best-fit lines and the resulting IC₅₀ values were calculated using log [inhibitor] versus normalized response—variable slope (four parameters).

Immunohistochemistry for CDK12 expression in GBM patients

Anonymized formalin-fixed and paraffin-embedded (FFPE) tissue samples from routine diagnostics were subjected to CDK12 immunohistochemistry. Minimal clinical data such as age, sex and final pathological diagnoses were included (see **supplementary table-1**). In brief, immunohistochemistry was performed on 2-3 µm thick slices of glioblastoma tissue (n = 5 patients) and on CNS tissue without glioblastoma (n = 2 patients) using an automated IHC staining system Dako Omnis (Agilent, Santa Clara, California, USA). For further details, please see supplementary table-1. Tissue from a patient with fasciitis was used as control tissue. The staining procedure included heat and chemical treatment of the slides with EnVision FLEX TRS at low pH at 97°C (20 min), incubation (30 min) with polyclonal rabbit-anti-human-CDK12 antibody (ab246887; Abcam; 1:50) and 3 min endogenous enzyme block with EnV FLEX Peroxidase-Blocking solution. Signal enhancement was achieved by incubating slides with EnV Flex + Rabbit LINKER (10 min). EnV FLEX/HRP labeled polymer (20 min) was used as secondary antibody, followed by incubation with the EnVision FLEX DAB Chromogen for 5 minutes. Slides were counterstained with hematoxylin and mounted with coverslipping film Tissue-Tek (Sakura, Staufen, Germany). Slides were then scanned in the Hamamatsu NanoZoomer 2.0-HT (Hamamatsu Photonics), digitized, and transferred to a computer screen. Brightness, gain, and contrast were all kept constant during image acquisition. Glioblastoma and CNS tissue as well

as control tissue were then assessed for immunoreactivity (negative, weak, moderate or strong) to CDK12 (see also Figure 2A/Supplementary figure 2A).

Supplementary Table 1 : Patients characteristics of the samples included

Patient No.	Slide No.	Age (y)	Gender	Tissue	Diagnosis
1	C12	81	female	Fascia	fasciitis
1	C13	81	female	Fascia	fasciitis
2	C18	40	male	CNS	Cavernous hemangioma
3	C14	59	female	CNS	Glioblastoma, CNS WHO grade 4
4	C15	74	female	CNS	cerebral amyloid angiopathy (CAA)
5	C16	85	female	CNS	glioblastoma, CNS WHO grade 4
6	C17	69	female	CNS	glioblastoma, CNS WHO grade 4
7	C19	64	male	CNS	glioblastoma, CNS WHO grade 4
8	C21	55	male	CNS	rest/recurrent glioblastoma, CNS WHO grade 4

Mouse experiments

SR-4835, from MedChemexpress was dissolved in 10% DMSO / 90% (30%) Hydroxypropyl- β -Cyclodextrin (hp-BCD) and TMZ from Selleckchem, was dissolved in 10% DMSO in distilled water and administered per os (PO). Weekly SR-4835 dosage was five days daily in the week with a two days break whereas TMZ dosage was daily. For the combination treatment, compounds were dosed at the same time with TMZ dosed first, followed by SR-4835. For a more detailed A subcutaneous U87-MG-luc model was established by Crown Bioscience Inc. (Leicester, UK) using the parental U87-MG cell line from ECACC, transduced in house to express luciferase. Animals were housed in IVC housing with a 12 h light/dark cycle and access to Teklad 2919 and sterile water ad libitum. **Tolerability experiment** Athymic nude mice aged 7-8 weeks old from Envigo were dosed with 20 mg/kg and 30 mg/kg SR-4835 for 2 weeks with the weekly cycle five days on and two days off. **Efficacy experiments** The *in vivo* efficacy of the SR-4835, either as a monotherapy or in combination with Temozolamide, was further evaluated in the clinically relevant subcutaneous CDX U87-MG-luc xenograft model. These experiments were conducted at Crown Bioscience, Inc. (Leicester, UK) in 7-8 week old athymic

nude mice (Envigo, UK). Forty-eight mice were enrolled in the efficacy study, eight mice per cohort for six cohorts. Eight million U-87-MG-luc cells were injected subcutaneously into athymic nude mice acquired from Envigo. All animals were randomly allocated to the six different study. Randomization was performed on day nine post injection, prior to the treatment start. The treatments were undertaken for 2 weeks with the five day on, 2 day off cycle per week for SR-4835 and daily for TMZ. Tumors were measured 3 times a week and tumor volumes were estimated by measuring the tumor in two dimensions using electronic callipers. **Humane Endpoints** Any mouse with tumor volume/measurement at terminal size (e.g. mean diameter 15mm) was terminated. After one measurement of body weight loss (BWL) > 10% on the day of dosing, a treatment break was given and treatment resumed when the body weight recovered to BWL < 5% (compared to day 1 treatment). Any mouse with BWL > 15% for 3 consecutive measurements (compared to day 1 treatment) was euthanized and any mouse with body weight loss \geq 20% was Schedule 1 culled.

Immuno-blotting

Cells were lysed directly in 1.25X Laemmli sample buffer, sonicated and denatured at 95°C for 5 minutes. Samples were loaded and the protein separated in Novex tris-glycine 6% gels (Life Technologies, XP00062BOX) and transferred to nitrocellulose membranes. Membranes were incubated in blocking buffer (5% FBS in TBST (TBS with 0.2% Tween-20) for 1.5h at room temperature and incubated with primary antibody (dilutions are indicated in the table below) in the blocking buffer overnight at 4°C. Membranes were given three washes in TBST for 10 minutes, then incubated 35 minutes with appropriate secondary antibodies in blocking buffer and washed for another 3x10 minutes. Chemiluminescent detection was performed using Chemiluminescent substrate kit from Fisher Scientific, catalog 34580.

Supplementary Table 2 : Antibody dilution

Antibody	Manufacturer	Catalog number	Dilution for CUT&RUN	Dilution for WB
RNAPII total	Mbl	MABI0601	1:100	1:10 000
RNAPII pSer2	Mbl	MABI0602	1:100	1:10 000
RNAPII pSer5	Mbl	MABI0603	1:100	1:10 000
H3K27ac	CST	D5E4	1:100	1:1000
H3K27me3	CST	C36B11	1:100	1:1000
RNAPII pThr4	Active Motif	61461	NA	1:1000
RNAPII pSer7	Active Motif	61087	NA	1:1000
Vinculin	Sigma	V9131	NA	1:10 000
PARP	CST	9542	NA	1:1000
GAPDH	Santa Cruz Biotechnology	sc25778	NA	1:20 000
IgG	abcam	ab6721	1:100	NA

qPCR primers are available on request

SLAM-seq

SLAM-seq was performed according to the previous described protocol ²⁶. Briefly, cells were seeded at approximately 70% confluency, and treated with THZ531 or vehicle control. 1 hour before harvest, 4sU was added to the medium at a final concentration of 500 μ M. The samples were kept in the dark as RNA was extracted with Qiagen's RNeasy Plus Mini Kit. 3 μ g RNA was alkylated with iodoacetamide (Sigma, 10 mM) for 15 minutes, and the RNA was repurified by ethanol precipitation. 250 ng RNA was used to make libraries with Lexogen's QuantSeq 3' mRNA-Seq Library Prep Kit FWD for Illumina and PCR Add-on Kit for Illumina. Deep sequencing was performed using the NovaSeq platform (Illumina).

CUT&RUN

Cells were treated with THZ531 or vehicle control before they were harvested, washed and bound to Concanavalin A-coated magnetic beads. The cells were then permeabilized with

wash buffer (20 mM HEPES, pH7.5, 150 mM NaCl, 0.5 mM spermidine and a Roche complete tablet per 50 ml) containing 0.02% Digitonin. The cell-bead suspension was incubated with 0.5-1 µg of respective antibody in a total volume of 50 µL overnight at 4°C on a nutator. After 3 washes with 1 mL Digitonin buffer, cells were resuspended in 50 µL volume with pAG-MNase and nutated for 10 minutes at RT. Cells were given two washes with Digitonin buffer, chilled on ice, and ice-cold CaCl₂ was added, before nutating for 2 hours at 4°C. STOP buffer was added (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 0.02% Digitonin, 50 µg/mL RNase A, 50 µg/ml glycogen), and tubes were incubated at 37°C for 10 minutes in a ThermoMixer, to release fragments into solution. After centrifugation at 16,000 x g for 5 minutes at 4°C, tubes were placed on a magnet stand and the liquid transferred to new tubes. DNA was extracted using Qiagen's MinElute PCR Purification Kit, according to manufacturer's instructions. Quantification was done by Qubit analysis, and libraries were made with 2 ng DNA using the NEBNext® Ultra™ II DNA Library Prep Kit for Illumina" (New England Biolabs, E7645), according to manufacturer's instructions. Deep sequencing was performed using the NovaSeq platform (Illumina).

SLAM-seq data processing

3' UTR annotations were obtained from ²⁹. All further processing was done on the Galaxy server, using the SlamDunk pipeline (<http://github.com/t-neumann/slamdunk>). Prior to mapping, the quality of the sequencing of the reads was inspected using FastQC (v.0.72+galaxy1) (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Adapters were trimmed from raw reads using cutadapt through the trim_galore (v.0.4.3.2) wrapper tool with adapter overlaps set to 3bp. The reads were then processed using SlamDunk (v.0.4.1+galaxy2). Settings were adjusted to alignment against the human genome (GRCh38),

12bp trimming from the 5' end, with multi-mapper retention strategy for 100 alignments, filtering for variants with a 0.2 variant fraction, filtering for base-quality cutoff of ≥ 27 , and filtering for ≥ 1 T>C conversions.

Cut&Run data processing

Prior to mapping, the quality of sequenced reads were inspected using FastQC (v. 0.10.1) (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), fastqScreen (v. 0.11.4, ⁴¹), and MultiQC (v. 1.7, ⁴²) and reads were mapped to hg38 using Bowtie2 (v. 2.2.9, ⁴³) and the settings "--local --very-sensitive-local --no-unal --no-mixed --no-discordant --phred33 -l 10 -X 700", and filtered for an insert size between 20 and 120 base pairs using samtools (v. 1.10, ⁴⁴) in accordance with instructions from the CUT&RUN protocol ⁴⁵ in the following pipe: "samtools view -h -f 66 | awk -F'\t' 'function abs(x){return ((x < 0.0) ? -x : x)} {if ((abs(\$9) >= 20 && abs(\$9) <= 120) || \$1 ~ /^@/) print \$0}' | samtools view -Sb - ". Filtered mapped reads were deduplicated and imported into EaSeq v. 1.2 ⁴⁶ using default settings and unless specified subsequent analysis and visualisation was performed using the integrated tools in EaSeq.

Genome-wide data sources

All Cut&Run and SLAM-seq data are deposited at NCBI's Gene Expression Omnibus ⁴⁷ under the accession number GSE186311. Refseq gene annotations ⁴⁸ were acquired from the UCSC table browser ⁴⁹. CDK and cyclin genes were identified based on matching the strings 'CDK' or 'CCN' to gene symbols. RPL/RPS gene symbols were obtained from <http://ribosome.med.miyazaki-u.ac.jp/rpg.cgi?mode=orglist&org=Homo%20sapiens>, Histone gene symbols were obtained from http://www.informatics.jax.org/mgihome/nomen/gene_name_initiative.shtml, house-

keeping gene symbols were obtained from ⁵⁰, DDR-gene symbols were obtained from <https://www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-genes.html>, BRCA-ness gene symbols were obtained from ⁵¹ and gene symbols for glioma transcription factors and targets were obtained from ¹¹.

Cut&Run and SLAM-seq visualization and integration

Graphs of average Cut&Run signal as well as heatmaps were generated in EaSeq using the 'Average' and 'HeatMap'-tools, respectively. K-means clustering was performed using the 'Cluster'-tool with the clustering methodology set to k-means, the offset set to +/-1kbp and log-transformation disabled. Output from the SLAM-seq processing was analysed for differential expression using DeSeq2 ⁵² with default settings, and size factors estimated on the total mRNA reads for global normalization. Transcripts were subgrouped according to adjusted p-values from the differential expression analysis, with the group 'Most down' having adjusted p-values below 10^{-5} and the group 'Less down' having adjusted p-values between 10^{-5} and 0.05. Volcano plots were generated based on log₂ fold differences and adjusted p-values from DeSeq2 and visualized using EaSeq and the 'Scatter'-tool or Microsoft Excel 2016. The number of selected gene subsets found within the significantly regulated genes was counted and compared to that expected by chance using Chi-square testing, and p-values for all shown comparisons were Bonferroni-adjusted before being plotted in bubble diagrams. Cut&Run values for 1D heatmaps of signal at TSSes were quantified using the 'Quantify'-tool and default settings except for using offsets of +/-1kbp and visualized together with 'basemean' and log₂ fold difference values from the DeSeq2 output of Nascent transcripts using the 'ParMap'-tool. The order of the TSSes was determined based on first the grouping as mentioned above, and then the average expression value in all conditions (Basemean). GO-term enrichment analysis of significantly regulated transcripts was done using g:Profiler (<https://biit.cs.ut.ee/gprofiler/>,

⁵³). Bee-swarm plots were made using the using R (<https://www.R-project.org/>) and the beeswarm package (The Bee Swarm Plot, an Alternative to Stripchart, version 0.2.0, A Eklund (2016), CRAN). Integration of expression data with cell-cycle related transcriptional changes was done using published results ³⁰. The 'polar coordinates' from transcripts that were found to be significant in their work was used as the X-axis when visualizing the moving average log₂ fold difference in the expression of 100 transcripts (Y-axis).

1 **Supplementary legends**

2 **Supplementary Figure 1:**

3 **(A)** Survival analyses from Gliovis showing relation between survival of patients and
4 expression of tCDK used in the study. **(B)** Heatmap showing the mRNA expression of tCDKs in
5 the cell lines used in the study. **(C)** Three high-grade glioma cell lines were cultured in serum-
6 free or serum-containing media and were treated with increasing doses of THZ531. After 72h,
7 the cell viability was assessed using Cell-Titer-Glo. Graph displays a dose-response curve with
8 percent cell viability relative to the DMSO control for each cell line. Data represent mean \pm SD
9 of three replicates. **(D)** Four high-grade glioma cell lines and two non-glioma cell lines were
10 treated with increasing doses of THZ1. After 72h, cells were subjected to the MTT assay. Graph
11 displays a dose-response curve with percent cell viability relative to the DMSO control for each
12 cell line. Data represent mean \pm SD of three replicates. **(E)** Four high-grade glioma cell lines
13 and two non-glioma cell lines were treated with increasing doses of NVP-2. After 72h, cells
14 were subjected to the MTT assay. Graph displays a dose-response curve with percent cell
15 viability relative to the DMSO control for each cell line. Data represent mean \pm SD of three
16 replicates. **(F)** Eight high-grade glioma cell lines and two non-glioma cell lines were treated
17 with increasing doses of SR-4835. After 72h, cells were subjected to the MTT assay. Graph
18 displays a dose-response curve with percent cell viability relative to the DMSO control for each
19 cell line. Data represent mean \pm SD of three replicates. **(G)** *in vitro* cell proliferation assay of
20 GSCs treated as indicated. Data represent mean \pm SD of two replicates. **(H)** Effect of THZ531
21 treatment on the migration of glioma cells. Average speed of migration is plotted over time.
22 Gefitinib, an EGFR inhibitor is used a positive control.

23 **Supplementary Figure 2:**

24 **(A)** Representative images of CDK12 immunohistochemistry in cortex/infiltration zone/cell-
25 rich tumor of glioblastoma patients. Nuclear CDK12 expression absent in cortex areas without
26 obvious tumor cell infiltration (top) while the number of CDK12-positive cells increases with
27 tumor cell density in the infiltration zone (CDK12-positive cells = black arrowhead; CDK12-
28 negative cortical neurons = blue arrowhead). Multinucleated giant cells (asterisk, bottom) in
29 highly cellular areas expressing CDK12. Scale bar 50 μm . **(B)** Summary of the patient
30 characteristics of the ex vivo GBM organoids. **(C)** Four high-grade glioma cell lines were treated
31 with increasing doses of inhibitors as indicated. After 72h, the cell viability was assessed using
32 Cell-Titer-Glo. Graph displays a dose-response curve with percent cell viability relative to the
33 DMSO control for each cell line. Data represent mean \pm SD of three replicates. **(D)** Dot-plot
34 showing IC50 values for dose response of inhibitors on a panel of GSCs shown in (C).

35 **Supplementary Figure 3:**

36 **(A)** Heatmaps of Cut&Run signal from RNAPII, RNAPII phosphorylation states, selected
37 histone mark modifications, as well as input at gene bodies and immediate upstream and
38 downstream regions (\pm 25% of gene length) from G7 cells treated with either THZ531 for 1
39 hr, or THZ531 for 6 hrs as well as DMSO controls. Genes were ordered vertically based on their
40 total expression level. The horizontal extent of each gene and the upstream and downstream
41 regions corresponding to quarter of the gene length is fitted within the same visual space in
42 the heatmaps regardless of its absolute extent. TSS and TTS illustrate transcription start sites
43 and termination sites, respectively. Cut&Run and input levels are FPKM normalized.
44 **(B)** Graphs of average Cut&Run signal from RNAPII phosphorylation states normalized to
45 RNAPII levels at all gene bodies and surrounding loci. RNAPII and RNAPII modification states
46 were obtained as described in Figure 4A. The horizontal extent of each gene and the upstream
47 and downstream regions corresponding to half a gene length is fitted within the same visual

48 space in the heatmaps regardless of its absolute extent. TSS and TTS illustrate transcription
49 start sites and termination sites, respectively. Cut&Run levels are FPKM normalized. (C) Bar
50 diagrams showing the most significantly enriched gene ontology (GO) terms from selected
51 subsets of genes from steady-state and nascent RNA. X-axes represent $-\log_{10}$ p-values
52 adjusted for multiple testing. (D) Volcano plots showing the overall transcriptional differences
53 in nascent transcripts as in Figure 3E, but with certain gene populations highlighted. X-axes
54 shows the \log_2 fold difference in transcription in G7 cells treated with THZ531 for six hours
55 compared to DMSO controls. Y-axis shows the $-\log_{10}$ transformed p-values Benjamini-
56 Hochberg corrected for multiple testing. Coloured dots illustrate the transcriptional changes
57 of the listed gene populations.

58 **Supplementary Figure 4:**

59 (A) Volcano plots showing the overall transcriptional differences in steady-state transcripts as
60 in Figure 3D, but with certain gene populations highlighted. X-axis shows the \log_2 fold
61 difference in transcription in G7 cells treated with THZ531 for six hours compared to DMSO
62 controls. Y-axis shows the $-\log_{10}$ transformed p-values Benjamini-Hochberg corrected for
63 multiple testing. Coloured dots illustrate the transcriptional changes of the listed gene
64 populations.

65 **Supplementary Figure 5:**

66 (A) Genome browser tracks of Cut&Run signal density and total transcript-levels (bottom) at
67 the Olig2, Pou3f2 and Sox2 loci at indicated treatments. (B-D) RT-qPCR analyses of the mRNA
68 levels of DDR genes (B), glioblastoma transcription factors (C) or housekeeping genes (D) in
69 G7 cells treated with 500 nM THZ531 for 1 h and 6 h. Data represent mean \pm SD of two
70 replicates.

71 **Supplementary Figure 6:**


72 (A) Venn-diagrams illustrating the overlap in the populations of genes being downregulated
73 (left) as well as upregulated (right) in G7 cells compared to G144 cells. (B) Graphs illustrated
74 the moving average of transcriptional changes in nascent (top) or steady-state (middle,
75 bottom) transcripts from G7 (top, middle) or G144 (bottom) cells treated with THZ531 for 6
76 hours compared to DMSO controls. Transcripts were ordered according to previously
77 published classification of cell-cycle timing. Only transcripts, for which transcriptional timing
78 could be assessed with an FDR-value of 0.001 or better, were included. (C) Beeswarm-plots of
79 transcriptional changes as in (B) with transcripts grouped into six overall groups based on
80 previously published transcriptional timing. P-values were obtained using Mann-Whitney U-
81 tests and Bonferroni-corrected for multiple testing. (D) Cells were treated with 500 nM
82 THZ531 at indicated times and EdU incorporation was performed in the last 1 hour by adding
83 10 μ M EdU. Cell staining was done using Click-IT chemistry according to manufacturer's
84 instructions.

85 **Supplementary movie 1 and 2:**


86 The movies include raw data with TrackMate overlay to show particle tracking of migrating G7
87 (Supplementary movie 1) and G144 cells (Supplementary movie 2). Prior to imaging, 6000
88 cells were seeded in wells of a 96-well glass plate and cells exposed to either DMSO (left panel)
89 or 500 nM THZ531 (right panel) overnight. Image acquisition was carried out using a 20x air
90 objective, a time interval of 4 min and a total imaging period of 8 h. The movie has been
91 reduced to show 50 frames. Scale bar is 10 μ m.

92


A




B




C




D




E




F







G




H



Supplementary Figure 2




Supplementary Figure 3



Supplementary Figure 4


A

Steady-state




Supplementary Figure 5

A




B

Expression of DDR genes following THZ531 treatment




C

Expression of glioblastoma transcription factors following THZ531 treatment



D

Expression of housekeeping genes following THZ531 treatment



Supplementary Figure 6

